NanoViricides wins DRC ethics approval for Phase II trial of NV-387 oral gummies for Ebola
NNVC•Regulatory filing next
The company is preparing to submit a clinical trial application to ACOREP, the DRC regulator, to start the study.
DRC ethics committee clears Phase II study
NanoViricides received DRC National Ethics Committee clearance for a Phase II trial of NV-387 oral gummies to treat Bundibugyo Ebola.
